TEVOGEN BIO reposted this
Thank you to the Canadian consulate for hosting a wonderful session spent learning about the opportunities and investment programs offered to AI companies to consider Canada to source talent and develop their technology.
Tevogen Bio brings together a highly skilled team of preeminent scientists, senior biopharmaceutical leaders, and manufacturing experts with the goal of advancing global health. The company’s patient centric mission is to leverage its proprietary cell and gene therapy platforms and novel business model to rapidly innovate breakthrough immunotherapies for cancers and viral infections with high unmet need. Tevogen Bio’s foundational vision is a healthier world through equitable access to lifesaving innovations.
External link for TEVOGEN BIO
15 Independence Blvd
Warren, New Jersey 07059, US
TEVOGEN BIO reposted this
Thank you to the Canadian consulate for hosting a wonderful session spent learning about the opportunities and investment programs offered to AI companies to consider Canada to source talent and develop their technology.
Please join TEVOGEN BIO's Advisory Board member, Afshin Beheshti, as he shares the latest advancements in space biology and medicine. Hosted by Universidad San Francisco de Quito, the event will be streamed on Tuesday, September 11th. #TVGN #celltherapy #biotech #leadership
Associate Professor at Universidad San Francisco de Quito, USFQ, MIT Technology Review Innovator Under 35, ISCT SCA Regional Vice-President Elect, ISCT Trailblazer Award, Best Invention and Innovation CEDIA 2024
Afshin Beheshti at the Space Front Universidad San Francisco de Quito Webinars! 🚀🌎 Dive into the latest advances in space biology and medicine with an expert🌌 📡Join us for the live stream on Tuesday, September 11th at 18:00 GMT-5 https://lnkd.in/eriGuArB https://lnkd.in/epAPgEwk Don’t miss out on updates for this and future events! Register here: 👉 https://lnkd.in/eZE36pwX Let’s build an international space ecosystem together. Go Artemis! 🌍✨ Ryan T. Scott David Alexander OBE University of Pittsburgh Felipe Ante Levoyer Damián Ramia Diego Quiroga Franklin Velasco Vizcaíno Marilyn Andino Borja Alexandra Velasco
Link: https://lnkd.in/dUPJBZnT A statement from The Patel Family, LLP reads, "Our commitment to a long-term position in Tevogen Bio stock reflects our conviction in its innovative approach to precision T cell therapies and to the leadership team. We believe they will ensure the company moves forward on its goals of helping patients and shareholders alike.” #TVGN #affordable #accessible #celltherapy #oncology #neurology #virology #biotech
Link: https://lnkd.in/gxueA7Cu Ryan Saadi, MD, MPH, Founder and CEO said "Tevogen’s leadership is focused on advancing our story by leveraging our unique technology platform and unwavering commitment to cost-effective operations. The company will look to sustain progress and expect to deliver value to patients and shareholders alike, now and into the future.” #TVGN #affordable #accessible #celltherapy #oncology #neurology #virology #biotech
🔗 https://lnkd.in/gUQMDiqA 🔗 Sharing his thoughts on his new appointment, Sten Vermund said "My time as Dean of the Yale School of Public Health was both productive and gratifying. Our alumni played a vital role in supporting us, with Ryan Saadi, MD, MPH at the forefront. When the Global Virus Network relocated its global headquarters to Tampa, an opportunity to move to the South Florida College of Public Health presented itself. I saw exciting new opportunities at the USF Health College of Public Health, a public institution that is innovating at many levels." #TVGN #leadership #affordable #accessible #celltherapy #oncology #neurology #virology #biotech
Link: https://lnkd.in/gtjpA2F8 Ryan Saadi, MD, MPH stated “Given the recent volatility across broader stock market indices as well as in TEVOGEN BIO stock, I want to express management’s conviction in the company’s strategy and outlook. Our ultimate objective of helping patients and doctors by providing affordable and accessible therapies remains unwavering. Our efficient business model uniquely underscores this objective. I anticipate the company’s most recent financing, for up to $50 million, which finalized in July, will allow us to continue to fund existing operations into the future.” #TVGN #affordable #accessible #celltherapy #oncology #neurology #virology #biotech
Dr. Neal Flomenberg, Chief Scientific Officer, discussed TEVOGEN BIO's goal of making cytotoxic #Tcell #immunotherapy a #mainstream, outpatient treatment, which he felt was achievable if the therapy was safe, affordable, readily - rapidly accessible, and comfortable for patients. $TVGN #affordable #accessible #celltherapy #oncology #neurology #virology #biotech
TEVOGEN BIO Founder and CEO Ryan Saadi, MD, MPH sat down with Deborah Balshem of Mergermarket to discuss the company's partnership and capital options. Distributed with permission from Deborah Balshem. #TVGN #affordable #accessible #celltherapy #oncology #neurology #virology #biotech Fundamental Research Corp. Zito Partners
Link ➡ https://lnkd.in/gDJnjJw2 “We remain committed to transparency and open communication with our stockholders. We believe that our ongoing efforts and strategic initiatives will position Tevogen Bio for sustained growth and success. Thank you for your continued trust and support,” - Ryan Saadi, MD, MPH Founder and CEO TEVOGEN BIO #TVGN #affordable #accessible #celltherapy #oncology #neurology #virology #biotech
Neal Flomenberg, Chief Scientific Officer, and Dolores Grosso, Clinical Development Lead, sit down with Nasdaq's Kristina Ayanian to discuss how TEVOGEN BIO is harnessing CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. #TVGN #affordable #accessible #celltherapy #oncology #neurology #virology #biotech